<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04954573</url>
  </required_header>
  <id_info>
    <org_study_id>30-387 ex 17/18</org_study_id>
    <nct_id>NCT04954573</nct_id>
  </id_info>
  <brief_title>Study on the Treatment With Water-filtered Infrared-A (wIRA) Radiation in Patients With Morphea and Sclerotic Graft-versus-host Disease</brief_title>
  <official_title>Pilot Study on the Treatment With Water-filtered Infrared-A (wIRA) Radiation in Patients With Morphea and Sclerotic Graft-versus-host Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical University of Graz</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medical University of Graz</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective, intra-individual comparative study to evaluate the effectiveness of&#xD;
      local-water filtered infrared-A (wIRA) irradiation (applied by Hydrosun® radiator 750 for&#xD;
      radiation at the clinic, or Hydrosun® 575home for home treatment) in patients with morphea or&#xD;
      sclerotic GVHD (Graft-versus-host Disease). The purpose of the study is to determine whether&#xD;
      wIRA irradiation can reduce fibrotic skin alterations in circumscribed scleroderma (morphea)&#xD;
      or chronic graft versus host disease. wIRA irradiation is applied for 30 minutes 3 times per&#xD;
      week for 20 weeks to a diseased skin area and a lesional skin on contralateral body site&#xD;
      remains untreated. A total of 22 patients (20 evaluable patients with an expected drop-out&#xD;
      rate of 10%) are to be included in this study. Group A: 11 patients with plaque morphea Group&#xD;
      B: 11 patients with sclerotic GVHD.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A sclerotic plaque or area of skin on the right side of the body and contralaterally on the&#xD;
      left half of the body (each maximum size: 25 cm in diameter, corresponding to the radiation&#xD;
      field of the Hydrosun® heater 750) is selected. The assignment of one side of the body to&#xD;
      irradiation or non-irradiation is randomized (using the MedUni Graz randomizer). The plaque&#xD;
      randomized for irradiation is irradiated on 3 days a week for 30 minutes each time. The&#xD;
      treatment period extends over 20 weeks, the total number of radiation treatments is therefore&#xD;
      60. If the patients cannot come to the radiation treatment, home therapy can be carried out&#xD;
      according to the same treatment scheme. The radiation at the clinic is carried out with a&#xD;
      Hydrosun® lamp 750, the home treatment with the Hydrosun® 575home (Hydrosun Medizintechnik&#xD;
      GmbH, Mauchener Str. 14, D-79379 Muellheim, Germany). The radiation intensity at the distance&#xD;
      of 33 cm between the device and the skin surface standardized by a distance rod is 200 mW /&#xD;
      cm2 (visible light 50 mW / cm2, infrared A 150 mW / m2). The contralateral plaque or skin&#xD;
      area of comparable clinical characteristics and duration of existence was included as an&#xD;
      unirradiated control. Target and control areas will be photo-documented in the course of the&#xD;
      study. Before the first irradiation, after the 30th and after the 60th irradiation, the skin&#xD;
      thickness and hardness of the target and control regions are measured by a blinded examiner&#xD;
      and the skin status including mRSS (Rodnan skin score) is recorded. In addition, at the&#xD;
      beginning and at the end of the study, the patient's assessment of the effect (PGIC scale)&#xD;
      and tolerability of the therapy is asked. Any side effects of the irradiation are&#xD;
      continuously documented.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 1, 2021</start_date>
  <completion_date type="Anticipated">June 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Intensity of skin sclerosis</measure>
    <time_frame>20 weeks</time_frame>
    <description>as determined by a high-frequency ultrasound device with a 22 MHz applicator</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Assessment of skin Score</measure>
    <time_frame>20 weeks</time_frame>
    <description>determined by modified Rodnan Skin Score (mRSS) (range, 0 to 51 )</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of skin hardness</measure>
    <time_frame>20 weeks</time_frame>
    <description>as determined by durometer</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of range of motions</measure>
    <time_frame>20 weeks</time_frame>
    <description>as measured by the range of motions in the presence of contractures (range, 0 to 90 degree)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Grade of patient satisfaction</measure>
    <time_frame>20 weeks</time_frame>
    <description>as determined by Patients' Global Impression of Change (PGIC) scale (range, 0 to 7)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">22</enrollment>
  <condition>Morphea (Circumscribed Scleroderma)</condition>
  <condition>Sclerotic Graft-versus-host Disease (GVHD)</condition>
  <arm_group>
    <arm_group_label>Morphea</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Sclerotic graft-versus-host disease (GVHD)</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>infrared-A (wIRA)</intervention_name>
    <description>Local-water filtered infrared-A (wIRA) irradiation</description>
    <arm_group_label>Morphea</arm_group_label>
    <arm_group_label>Sclerotic graft-versus-host disease (GVHD)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Morphea&#xD;
&#xD;
          -  Sclerotic graft-versus-host disease (GVHD)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Inability to cope with the treatment plan&#xD;
&#xD;
          -  Pregnant or breastfeeding women and women of childbearing potential without effective&#xD;
             contraception&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Peter Wolf, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical University of Graz</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Peter Wolf, MD</last_name>
    <phone>00 43 316 385</phone>
    <phone_ext>80315</phone_ext>
    <email>peter.wolf@medunigraz.at</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Alexandra Gruber-Wackernagel, MD</last_name>
    <phone>0043 316 385</phone>
    <phone_ext>13254</phone_ext>
    <email>peter.wolf@medunigraz.at</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Department of Dermatology, Medical University of Graz</name>
      <address>
        <city>Graz</city>
        <state>Styria</state>
        <zip>8036</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Peter Wolf, MD</last_name>
      <phone>031638580315</phone>
      <email>peter.wolf@medunigraz.at</email>
    </contact>
    <contact_backup>
      <last_name>Alexandra Gruber-Wackernagel, MD</last_name>
      <phone>00 43 316 385</phone>
      <phone_ext>13254</phone_ext>
      <email>alexandra.wackernagel@medunigraz.at</email>
    </contact_backup>
    <investigator>
      <last_name>Wolfgang Salmhofer, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Angelika Hofer, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Franz Legat, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Department of Dermatology, Medical University of Vienna</name>
      <address>
        <city>Vienna</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Adrian Tanew, MD</last_name>
      <phone>+43 1 40400</phone>
      <phone_ext>77070</phone_ext>
      <email>adrian.tanew@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Paul Jauker, MD</last_name>
      <phone>+43 1 40400</phone>
      <phone_ext>77070</phone_ext>
      <email>paul.jauker@meduniwien.ac.at</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Austria</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>June 9, 2021</study_first_submitted>
  <study_first_submitted_qc>June 29, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 8, 2021</study_first_posted>
  <last_update_submitted>July 12, 2021</last_update_submitted>
  <last_update_submitted_qc>July 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Scleroderma, Localized</mesh_term>
    <mesh_term>Graft vs Host Disease</mesh_term>
    <mesh_term>Sclerosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

